

NeuroMetrix to Exhibit at the 2012 Diabetic Foot Global Conference

Will Support a Hands-On Workshop on Evaluation of Diabetic Peripheral Neuropathy

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 12, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes will be an exhibiting sponsor at the Diabetic Foot Global Conference (DFCon) from March 15-17 in Los Angeles.

"We are pleased to play a leading role at this conference and showcase NC-stat® DPNCheck™, a diagnostic test that is useful in early detection and monitoring of diabetic peripheral neuropathy (DPN)," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer, NeuroMetrix. "Medical professionals participating in the diabetes workshop will receive valuable exposure to a fast, accurate, and quantitative point-of-care approach to the early detection of DPN which affects over 50% of people with diabetes and can lead to foot ulcers and amputation. This is an opportunity to demonstrate our medical device that aids in DPN diagnosis as well as to broaden company exposure in the medical community."

In addition to exhibiting at the conference, NeuroMetrix will have a demonstration area during the hands-on workshop session at the conference. The title of the workshop is "Dressings and Diagnostics" and will feature a presentation titled "Quantitative Evaluation of Diabetic Peripheral Neuropathy". It will be held on Saturday, March 17.

The Diabetic Foot Global Conference is focused on amputation prevention, diabetes management, and diabetic foot and diabetic wound care. It includes scientific and clinical lectures and specialized workshops. It is one of the premier annual conferences addressing the long-term implications of diabetes including diabetic neuropathy. Attendees include endocrinologists, podiatrists, primary care doctors and other medical professionals specializing in diabetic care.

About NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit <http://www.neurometrix.com>.

Source: NeuroMetrix

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com